Literature DB >> 18537587

The "classical" ovalbumin challenge model of asthma in mice.

Rakesh K Kumar1, Cristan Herbert, Paul S Foster.   

Abstract

Ovalbumin challenge models of asthma offer many opportunities for increasing our understanding of the pathogenetic mechanisms underlying this disease, as well as for identifying novel therapeutic targets. There is no single "classical" model, because numerous alternatives exist with respect to the choice of mouse strain, method of sensitisation, route and duration of challenge, and approach to assessing the host response. Moreover, the limitations of these models need to be recognised when attempting to interpret experimental findings. Nevertheless, careful use of well-defined models allows investigators to answer specific questions that are otherwise difficult to address.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537587     DOI: 10.2174/138945008784533561

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  71 in total

1.  Characterization of a novel model incorporating airway epithelial damage and related fibrosis to the pathogenesis of asthma.

Authors:  Simon G Royce; Krupesh P Patel; Chrishan S Samuel
Journal:  Lab Invest       Date:  2014-09-29       Impact factor: 5.662

Review 2.  Regulation of CD4 T-cell differentiation and inflammation by repressive histone methylation.

Authors:  Frann Antignano; Colby Zaph
Journal:  Immunol Cell Biol       Date:  2015-01-13       Impact factor: 5.126

3.  Serelaxin enhances the therapeutic effects of human amnion epithelial cell-derived exosomes in experimental models of lung disease.

Authors:  Simon G Royce; Krupesh P Patel; WeiYi Mao; Dandan Zhu; Rebecca Lim; Chrishan S Samuel
Journal:  Br J Pharmacol       Date:  2019-05-07       Impact factor: 8.739

4.  Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Authors:  Shailendra R Singh; Nikol Sullo; Maria Matteis; Giuseppe Spaziano; John McDonald; Ruth Saunders; Lucy Woodman; Konrad Urbanek; Antonella De Angelis; Raffaele De Palma; Rachid Berair; Mitesh Pancholi; Vijay Mistry; Francesco Rossi; Remo Guerrini; Girolamo Calò; Bruno D'Agostino; Christopher E Brightling; David G Lambert
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

Review 5.  Murine models for mucosal tolerance in allergy.

Authors:  Ursula Smole; Irma Schabussova; Winfried F Pickl; Ursula Wiedermann
Journal:  Semin Immunol       Date:  2017-08-12       Impact factor: 11.130

6.  MicroRNA Targets for Asthma Therapy.

Authors:  Sabrina C Ramelli; William T Gerthoffer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

Review 8.  Re-defining the unique roles for eosinophils in allergic respiratory inflammation.

Authors:  E A Jacobsen; N A Lee; J J Lee
Journal:  Clin Exp Allergy       Date:  2014-09       Impact factor: 5.018

9.  Chemotaxis of bone marrow derived eosinophils in vivo: a novel method to explore receptor-dependent trafficking in the mouse.

Authors:  Eva M Sturm; Kimberly D Dyer; Caroline M Percopo; Akos Heinemann; Helene F Rosenberg
Journal:  Eur J Immunol       Date:  2013-06-14       Impact factor: 5.532

10.  Comparison of adjuvant and adjuvant-free murine experimental asthma models.

Authors:  M L Conrad; A O Yildirim; S S Sonar; A Kiliç; S Sudowe; M Lunow; R Teich; H Renz; H Garn
Journal:  Clin Exp Allergy       Date:  2009-05-03       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.